Parvovirus B19-induced hemophagocytic lymphohistiocytosis: Case report and review of the literature.

CASE PRESENTATION

Hemophagocytic lymphohistiocytosis (HLH) is an inflammatory disorder that in adults is typically a complication of infection, malignancy, or rheumatologic disease. Rarely, patients develop Parvovirus B19‐induced HLH (PVB19‐HLH). A 51‐year‐old female with HLH demonstrated bone marrow positivity for PVB19 DNA suggesting PVB19‐HLH. Despite steroids and chemotherapy, the patient passed away.

A 51‐year‐old female from Indonesia (last visit in 2012) with a history of papillary thyroid cancer post‐thyroidectomy/iodine ablation presented with fever, cough, and 6.4 kg unintentional weight loss over the course of 1 month. Admission laboratories were significant for hemoglobin 8.1 g/dL (Range 12‐16 g/dL) and ferritin 1159 ng/mL (Range 4.6‐204 ng/mL). Admission platelets and leukocyte counts were within normal limits. Temperature was >39.5°C though physical examination was unremarkable including no evidence of gastrointestinal bleed to explain anemia. Imaging revealed no organomegaly or evidence of malignancy; however, nodular pulmonary opacification suspicious for pneumonia prompted antibiotics. Blood smear was negative for schistocytes, and flow cytometry was negative for blasts. Rheumatologic workup including antinuclear antibody, rheumatoid factor, dsDNA testing and complements were within normal limits. During the first 5 days of admission, the patient remained persistently febrile prompting broadening of her antibiotic regimen, her anemia worsened necessitating transfusion, and thrombocytopenia developed. Subsequent bronchoscopy including cultures was unremarkable for an infectious etiology. Multiple sets of blood cultures returned negative while Parvovirus serology was significant for a positive IgG, negative IgM, and negative DNA PCR. By hospital day 7, the patient developed new oxygen requirement and became hemodynamically unstable necessitating ICU transfer. Ferritin was rechecked and had increased to 3727 ng/mL raising concern for HLH. CT and ultrasound imaging demonstrated no evidence of thyroid malignancy recurrence. Triglycerides were elevated to 425 mg/dL (range <150 mg/dL) while abdominal ultrasound demonstrated splenomegaly. Bone marrow examination demonstrated hemophagocytosis and nuclear inclusions suggesting Parvovirus infection thus raising concern for PVB19‐HLH. Antibiotics were discontinued, and dexamethasone 10 mg/m 2 was started on hospital day 12 with subsequent defervescence; however, her cytopenias persisted and by hospital day 16 the patient's respiratory status declined necessitating intubation. Fevers recurred prompting reintroduction of antibiotics and repeat bronchoscopy including cultures was again unremarkable. Cyclosporine A 200 mg twice daily was started with dose up‐titration to 250 mg twice daily. sCD25 returned markedly elevated at 98 500 pg/mL (Range <1033 pg/mL) while qualitative bone marrow PVB19 DNA PCR returned positive on hospital day 19 consistent with PVB19‐HLH. A 5‐day course of intravenous immunoglobulin (IVIG) 0.4 g/kg was completed with subsequent clinical improvement, successful extubation, and increased hemoglobin and platelet values. Cyclosporine A was discontinued while the patient remained on dexamethasone taper and was transferred out of the ICU. By hospital day 26, the patient clinically continued to improve however remained intermittently febrile with fluctuating blood counts and increased ferritin values up to 13 684 ng/mL prompting discussion of adding etoposide, however the patient remained clinically stable and by hospital day 30 ferritin had down‐trended without new intervention to 8084 ng/mL. On hospital day 35, the patient began to develop recurrent dyspnea with a repeat ferritin of 15 658 ng/mL prompting addition of etoposide 150 mg/m 2 . By hospital day 36, the patient became hemodynamically unstable and acidotic prompting a second transfer to the ICU. Despite broad‐spectrum antibiotics, fluid resuscitation, and vasopressor support, the patient eventually passed away.

DISCUSSION

The histiocytoses are a heterogeneous group of diseases characterized by pathologic buildup of cells such as macrophages within tissues. 1 While macrophages are normally involved in clearance of cellular debris and pathogenic organisms, these same cells can trigger life‐threatening illness such as HLH. 1 HLH is a rare and aggressive form of histiocytosis characterized by histiocyte activation, dysregulated cytokine release, and systemic inflammation causing multiorgan failure. HLH was initially described in 1939 as “Histiocytic Medullary Reticulosis” though was later subdivided into primary and secondary types. 2 Primary HLH predominantly affects children and is caused by mutations in genes relating to perforin function and vesicular trafficking (PFR1, UNC13D, and STX11) or as a manifestation of inherited immunodeficiency syndromes such as Chédiak‐Higashi syndrome. 3 , 4 , 5 , 6 Primary HLH is invariably lethal without immunomodulation and stem cell transplant. 3 , 4 Secondary HLH is historically described in patients with no known genetic predisposition, generally arises in adolescents and adults and is typically a sequelae of infection (Epstein‐Barr Virus [EBV], human immunodeficiency virus [HIV], cytomegalovirus [CMV]), or malignancy (Lymphoma). 7 In the setting of rheumatologic diseases such as systemic lupus erythematosus and adult Still's disease, HLH is generally referred to as macrophage activation syndrome. 5 More recently, case reports exist demonstrating primary HLH in elderly patients and there is increasing evidence of genetic predisposition in patients with secondary HLH complicating the future division of HLH into 2 specific subtypes. 5 , 6 HLH in general has a reported prevalence of 1/100 000 though this is felt to likely increase as awareness of the disorder increases, as genetic testing improves and becomes more ubiquitous, and as diagnostic criteria for HLH become more specific. 6 Survival data vary based on underlying etiology and subtype of HLH, with reported mortality rates for secondary HLH ranging from 20% up to 85% for HLH associated with malignancies such as T‐cell lymphoma. 6 , 8

Current diagnostic criteria for both primary and secondary HLH are based on 2004 criteria set forth by the Histiocyte Society representing some of the common findings in the disorder (Table 1 ). 9 Using the HLH‐2004 criteria, demonstrating positivity for 5 criteria is considered sufficient for diagnosis and absence of any one criteria, including hemophagocytosis, does not exclude the diagnosis. Of note, these criteria were created specifically for the pediatric population and do not take into account other laboratory findings common in adult HLH patients such as elevated inflammatory markers, increased lactate dehydrogenase values, transaminitis and hepatic dysfunction, encephalopathy, and coagulopathy. 5 , 9 As a result, other authors have proposed alternative diagnostic criteria such as the HScore recently validated in adult patients with secondary HLH. 10 The HScore uses additional criteria such as immunosuppression and AST value to calculate a probability score between 0 and 337 with values >169 felt to accurately classify 90% of secondary HLH patients. 10 Using both the HLH‐2004 and HScore as diagnostic tools, our patient met 7/8 HLH‐2004 criteria (fever, splenomegaly, cytopenias, hypertriglyceridemia, hyperferritinemia, hemophagocytosis, and elevated sCD25) and an HScore of 264 with reported >99% probability of HLH.

Regardless of the underlying etiology for HLH, immune system hyperactivity leads to excessive release of inflammatory mediators including tumor necrosis factor‐alpha (TNF‐α), interleukin‐6 (IL‐6), and interferon‐gamma (IFN‐γ) producing a cytokine storm that leads to macrophage and T‐cell activation and subsequently the clinical signs and symptoms of HLH. 6 , 11 Given our patient developed HLH in the setting of persistent PVB19 marrow infection, here we focus on viral etiologies of secondary HLH, also known as viral‐associated hemophagocytic syndrome (VAHS).

Viral‐associated hemophagocytic syndrome was first noted in 1979 which subsequent literature conflictingly describes both as a rare disease carrying >30% mortality as well as an underdiagnosed yet benign clinical entity. 12 , 13 , 14 The underlying virion may have implications for prognosis and management thus some authors recommend extensive diagnostic workup. For example, treatment recommendations for EBV‐VAHS include corticosteroids, IVIG, etoposide, and rituximab. 15 While VAHS is most commonly associated with EBV, other implicated viruses include CMV, HIV, Herpes Simplex, and rarely PVB19. 16

PVB19 is a single‐stranded DNA erythrovirus with a tropism for bone marrow progenitor cells 17 , 18 producing characteristic bone marrow findings as demonstrated in our patient (Figure 1 ). The PVB19 genome produces the nonstructural protein (NS1) and capsid proteins VP1/VP2 which facilitate viral entry into marrow cells. 19 , 20 PVB19 infection is ubiquitous, with 50% of adolescents and upwards of 80% of the elderly population demonstrating evidence of serologic conversion (as noted by anti‐PVB19 IgG). 17 , 18 , 20 PVB19 infection can be diagnosed by detection of either serum IgM/IgG or by DNA PCR. However, due to PVB19 tropism for the marrow utilization of serum samples to document clearance of infection is considered less sensitive than using bone marrow samples. 18 In a study looking at detection of PVB19 antibodies and DNA in the serum and bone marrow, 112 patients demonstrated IgG positivity and negative IgM with 4 patients additionally demonstrating positivity for PVB19 DNA in the bone marrow but not the serum. 18 These authors concluded that in low‐grade and chronic infections the serum viral copy number may be so low as to be undetectable while the marrow remains positive for PVB19. 18 This population of immunocompetent individuals who develop chronic marrow infection as demonstrated by qualitative DNR PCR in the absence of positive serum DNA PCR or IgM are referred to as “persistently infected” and have been described as exhibiting the same fever and cytopenias that characterize HLH. 21 , 22

PVB19 is associated with a wide array of clinical manifestations depending on the immune status of the host. Healthy individuals acutely infected with PVB19 are known to develop erythema infectiosum, arthropathy, and transient anemia. 21 , 22 Immunosuppressed patients infected with PVB19 may develop persistent bone marrow suppression, vasculitis, myocarditis, and thrombotic microangiopathy. 16 , 23 Given the relationship between PVB19 infection and cytopenias in patients with history of malignancy, PVB19 infection can be mistaken for cancer recurrence. 17 This was an initial concern with our patient however thorough evaluation of the thyroid bed, chest, abdomen, and pelvis demonstrated no evidence of recurrent malignancy. Acute PVB19 infection is characterized by immune‐cell activation and cytokine dysregulation as lymphocytes produce IL‐2 and IFN‐γ in response to VP1/VP2 proteins while NS1 upregulates transcription of IL‐6. 24 , 25 Elevated inflammatory cytokine levels are detectible following initial PVB19 infection which when combined with persistent marrow infection are felt to contribute to development of PVB19‐HLH. 23 , 24 , 26 Interestingly, a TNF‐α polymorphism in specific Asian populations has been associated with increased susceptibility to secondary HLH. 11 This further suggests a possible genetic predisposition for development of secondary HLH, and while unproven may have contributed to our patient to developing PVB19‐HLH.

On review of PVB19‐HLH literature, the most commonly affected patient populations are the pediatric, immunocompromised, and those with hematologic pathology. 16 , 23 Compared with other etiologies of secondary HLH, patients with PVB19‐HLH have conflictingly been described as having a relatively benign course demonstrating recovery without specific pharmacologic intervention 11 , 23 , 27 as well as having increased mortality compared to other HLH etiologies. 28 There is suggestion that despite currently being considered rare, PVB19‐HLH may actually be underdiagnosed. 12 , 13 , 27 Of a Japanese study of 567 patients with HLH, 163 were found to have EBV‐HLH compared to three with PVB19‐HLH. 8 2 case reports of transplant patients developing PVB19‐HLH describe recovery despite immunosuppression. 23 , 29 Similarly, 2 cases of PVB19‐HLH in pregnancy describe females who recovered and delivered healthy children 30 , 31 while 7 cases of PVB19‐HLH in patients with underlying hematologic aberration exhibited recovery either with corticosteroids or no specific intervention. 12 , 26 , 32 , 33 , 34 , 35 Eleven cases of PVB19‐HLH in reportedly healthy individuals were found, where eight patients recovered either with steroids or no treatment, while the other three suffered from multiorgan dysfunction before passing away despite steroids, IVIG, and/or etoposide. 16 , 27 , 36 , 37 , 38 Only 9 cases actually described meeting five or more diagnostic criteria: Six of these patients recovered with either no intervention, steroids, and/or IVIG while the other three succumbed to their disease. 27 , 29 , 36 , 37 , 38 , 39 , 40

No specific antiviral drug currently exists directed toward PVB19, and while healthy adults often require only supportive care, IVIG has been shown to increase reticulocyte count and hemoglobin level. 41 Of PVB19‐HLH patients who received IVIG (including the current case), four eventually succumbed to disease complications, two were solid‐organ transplant recipients who recovered, and a single patient had multiple myeloma whose outcome was not discussed. 23 , 29 , 36 , 39 , 41 , 42 Unfortunately, treatment of PVB19‐HLH and VAHS overall remains challenging. Treatment regimens for HLH are again based on the HLH‐94 and HLH‐2004 protocols designed for pediatric populations and typically include some combination of etoposide, corticosteroids, cyclosporine A, IVIG, and allogeneic stem cell transplant. 9 , 43 However, while etoposide‐based regimens have demonstrated enhanced survival in pediatric patients with primary HLH, data regarding the survival benefit to etoposide in adult patients is inconsistent with authors describing alternative therapeutic options such as doxorubicin‐based regimens, plasma exchange, anti‐CD52 therapy with alemtuzumab, and anti‐IL‐6 therapy with tocilizumab. 9 , 44 For PVB19‐HLH and VAHS patients, published interventions include antivirals, IVIG, immunomodulatory agents, and corticosteroids; however, these have produced variable results. 3 , 4 , 7 Indeed, while at different points our patient received IVIG, cyclosporine A, corticosteroids, and etoposide she eventually suffered a terminal decline.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTION

JK: is an internal medicine resident, provided direct patient care, and served as the primary author of manuscript. SM: is a hematology/oncology fellow, provided direct patient care, and provided guidance with paper direction and edits of the manuscript. GF: is a pathology resident, provided pathology images included in the manuscript, and provided guidance with paper direction and edits of the manuscript. EK: is a pulmonary/critical care attending physician, provided direct patient care, and provided guidance with paper direction and edits of the manuscript. ML: is a hematology/oncology attending physician, provided direct patient care, and oversaw the manuscript.

Supporting information

Click here for additional data file.

Kalmuk J, Matar S, Feng G, Kilb E, Lim MY. Parvovirus B19‐induced hemophagocytic lymphohistiocytosis: Case report and review of the literature. Clin Case Rep. 2019;7:2076–2081. 10.1002/ccr3.2401

REFERENCES

1. Emile J‐F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage‐dendritic cell lineages. Blood. 2016;127(22):2672‐2681.

2. Scott RB, Robb‐Smith A. Histiocytic medullary reticulosis. The Lancet. 1939;234(6047):194‐198.

3. Machowicz R, Janka G,Wiktor‐Jedrzejczak W. Your critical care patient may have HLH (hemophagocytic lymphohistiocytosis). Crit Care. 2016;20(1):215.

4. Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. QJM. 2017;111(1):23‐31.

5. Hayden A, Park S, Giustini D, Lee A, Chen L. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30(6):411‐420.

6. Brisse E, Matthys P, Wouters CH. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br J Haematol. 2016;174(2):175‐187.

7. Ramos‐Casals M, Brito‐Zerón P, López‐Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. The Lancet. 2014;383(9927):1503‐1516.

8. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58.

9. Henter J‐I, Horne A, Aricó M, et al. HLH‐2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124‐131.

10. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613‐2620.

11. Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93‐105.

12. Muir K, Todd W, Watson WH, Fitzsimons E. Viral‐associated haemophagocytosis with parvovirus‐B19‐related pancytopenia. The Lancet. 1992;339(8802):1139‐1140.

13. Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine. 1988;67(6):369‐388.

14. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus‐associated hemophagocytic syndrome a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 1979;44(3):993‐1002.

15. La Rosee P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Edu Program. 2015;2015(1):190‐196.

16. Bal A, Mishra B, Singh N, Das A, Jindal SK. Fulminant parvovirus B19‐ associated pancarditis with haemophagocytic lymphohistiocytosis in an immunocompetent adult. Apmis. 2009;117(10):773‐777.

17. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285‐304.

18. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol. 2002;40(3):933‐936.

19. Isa A, Norbeck O, Hirbod T, et al. Aberrant cellular immune responses in humans infected persistently with parvovirus B19. J Med Virol. 2006;78(1):129‐133.

20. Mitchell LA. Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin‐6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol. 2002;67(2):267‐274.

21. Lundqvist A, Tolfvenstam T, Brytting M, Stolt CM, Hedman K, Broliden K. Prevalence of parvovirus B19 DNA in bone marrow of patients with haematological disorders. Scand J Infect Dis. 1999;31(2):119‐122.

22. Lundqvist A, Tolfvenstam T, Bostic J, Söderlund M, Broliden K. Clinical and laboratory findings in immunocompetent patients with persistent parvovirus B19 DNA in bone marrow. Scand J Infect Dis. 1999;31(1):11‐16.

23. Ardalan MR, Shoja MM, Tubbs RS, Esmaili H, Keyvani H. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am J Transplant. 2008;8(6):1340‐1344.

24. Kerr JR, Cunniffe VS, Kelleher P, Coats A, Mattey DL. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro‐inflammatory cytokines and development of B19associated arthritis. J Med Virol. 2004;74(1):147‐155.

25. Moffatt S, Tanaka N, Tada K, et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin‐6 gene expression. J Virol. 1996;70(12):8485‐8491.

26. Watanabe M, Shimamoto Y, Yamaguchi M, Inada S, Miyazaki S, Sato H. Viral‐associated haemophagocytosis and elevated serum TNF‐α with parvovirus‐B19‐ related pancytopenia in patients with hereditary spherocytosis. Clin Lab Haematol. 1994;16(2):179‐182.

27. Larroche C, Scieux C, Honderlick P, Piette AM, Morinet F, Blétry O. Spontaneous resolution of hemophagocytic syndrome associated with acute parvovirus B19 infection and concomitant Epstein‐Barr virus reactivation in an otherwise healthy adult. Eur J Clin Microbiol Infect Dis. 2002;21(10):739‐742.

28. Mishra B, Varma N, Appannanavar S, et al. Viral markers in patients with hemophagocytosis: a prospective study in a tertiary care hospital. Indian J Pathol Microbiol. 2012;55(2):215.

29. Tavera M, Petroni J, León L, Minue E, Casadei D. Reactive haemophagocytic syndrome associated with parvovirus B19 in a kidney pancreas transplant patient. Nefrologia. 2012;32(1):125‐126.

30. Duenas O, Gupta S, Rico H, Agarwal A. Parvovirus B‐19 associated hemophagocytic reactive syndrome during pregnancy. Fertil Steril. 2007;88:S228.

31. Mayama M, Yoshihara M, Kokabu T, Oguchi H. Hemophagocytic lymphohistiocytosis associated with a parvovirus B19 infection during pregnancy. Obstet Gynecol. 2014;124(2):438‐441.

32. Sato T, Ueda D, Sakota S‐I, Haseyama K, Chiba S, Kudoh T. Pancytopenia with hemophagocytosis secondary to parvovirus B19 infection in a family with hereditary spherocytosis. Pediatr Int. 1999;41(5):561‐564.

33. Koduri PR, Naides SJ. Transient blood plasmacytosis in parvovirus B19 infection: a report of two cases. Ann Hematol. 1996;72(1):49‐51.

34. Uike N, Miyamura T, Obama K, Takahira H, Sato H, Kozuru M. Parvovirus B19‐associated haemophagocytosis in Evans syndrome: aplastic crisis accompanied by severe thrombocytopenia. Br J Haematol. 1993;84(3):530‐532.

35. Sekiguchi Y, Shimada A, Imai H, et al. A case of recurrent autoimmune hemolytic anemia during remission associated with acute pure red cell aplasia and hemophagocytic syndrome due to human parvovirus B19 infection successfully treated by steroid pulse therapy with a review of the literature. Int J clin Exp Pathol. 2014;7(5):2624.

36. De Maria A, Zolezzi A, Passalacqua G, et al. Melkersson–Rosenthal syndrome associated with parvovirus b19 viraemia and haemophagocytic lymphohistiocytosis. Clin Exp Dermatol. 2009;34(8):e623‐e625.

37. Shirono K, Tsuda H. Parvovirus B19‐associated haemophagocytic syndrome in healthy adults. Br J Haematol. 1995;89(4):923‐926.

38. Yuan C, Asad‐Ur‐Rahman F, Abusaada K. A rare case of hemophagocytic lymphohistiocytosis associated with parvovirus B19 infection. Cureus. 2016;8:11.

39. Pedrosa AF, Mota A, Morais P, et al. Haemophagocytic syndrome with a fatal outcome triggered by parvovirus B19 infection in the skin. Clin Exp Dermatol. 2014;39(2):222‐223.

40. Karrasch M, Felber J, Keller PM, et al. Primary epstein‐barr virus infection and probable parvovirus B19 reactivation resulting in fulminant hepatitis and fulfilling five of eight criteria for hemophagocytic lymphohistiocytosis. Int J Infect Dis. 2014;28:143‐146.

41. Katragadda L, Shahid Z, Restrepo A, Muzaffar J, Alapat D, Anaissie E. Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease. Transpl Infect Dis. 2013;15(4):354‐360.

42. Matsumoto Y, Naniwa D, Banno S, Sugiura Y. The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Therapeutic Apheresis. 1998;2(4):300‐304.

43. Henter J‐I,Samuelsson‐Horne A, Aricò M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH‐94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367‐2373.

44. Shah AR, Muzzafar T, Assi R, et al. Hemophagocytic lymphohistiocytosis in adults: an under recognized entity. BBA clinical. 2017;7:36‐40.

Associated Data

Supplementary Materials

Click here for additional data file.